How to appeal a Cigna atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for atopic dermatitis (ad / eczema)

Cited policy: Cigna Rinvoq (Upadacitinib) for Moderate-Severe AD PA

Age >=12 yr per Apr 2022 label. Moderate-severe AD by IGA / EASI. Step-therapy: inadequate response or contraindication to >=1 systemic immunosuppressant OR Dupixent. JAK boxed-warning screening: TB, HBV/HCV, lipids, malignancy hx, VTE hx, smoking, MACE risk. Reauth 16 wk EASI-75 or NRS-4.

How Cigna denies atopic dermatitis (ad / eczema) — and how to counter it

Where Cigna pushes back: 1) JAK black-box requires 2 biologic failures first; 2) ORAL Surveillance — too risky.

Counter-arguments that hold up: ORAL Surveillance (Ytterberg NEJM 2022) was RA-specific (IL-6-driven, mean age 61, ≥1 CV risk factor, prior MTX failure). AD population (MEASURE UP-1/2 Guttman-Yassky Lancet 2021; AD-UP Reich; Heads Up Blauvelt JAMA Derm 2021) is younger, lower CV risk, IL-13-driven — different risk-benefit. Heads Up: upadacitinib 30 mg SUPERIOR to dupilumab on EASI-75 at 16 wk. JADE COMPARE (Bieber NEJM 2021) abrocitinib 200 mg SUPERIOR to dupilumab on EASI-90 + itch at 12 wk. Class switching after Dupixent partial-response is rational and supported by Level-1 evidence. AAD 2024 + AAAAI 2023 endorse JAK as parallel option with shared decision-making.

What Cigna typically denies for atopic dermatitis (ad / eczema)

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.